Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 2/20 | 0.73 |
| ▸ | MC4R | P32245 | 3/20 | 0.66 |
| ▸ | MC5R | P33032 | 2/20 | 0.66 |
| ▸ | MC3R | P41968 | 2/20 | 0.66 |
| ▸ | MC1R | Q01726 | 2/20 | 0.66 |
| ▸ | CXCR4 | P61073 | 7/20 | 0.61 |
| ▸ | GLP1R | P43220 | 1/20 | 0.60 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.59 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.57 |
| ▸ | PTH1R | Q03431 | 4/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29533913 | 0.98 | C5AR1 (0.75) | C5AR1MC4RMC5RMC3RMC1R | |
| SCHEMBL13478067 | 0.97 | C5AR1 (0.70) | C5AR1MC4RMC5RMC3RMC1R | |
| SCHEMBL18281742 | 0.92 | MC4R (0.77) | C5AR1MC4RMC5RMC3RMC1R | |
| SCHEMBL18281737 | 0.92 | MC4R (0.77) | C5AR1MC4RMC5RMC3RMC1R | |
| SCHEMBL30312751 | 0.92 | MC4R (0.77) | C5AR1MC4RMC5RMC3RMC1R | |
| Norleusactide SCHEMBL38665957 | 0.92 | C5AR1 (0.76) | C5AR1MC4RMC5RMC3RMC1R | |
| SCHEMBL30427315 | 0.91 | C5AR1 (0.72) | C5AR1MC4RMC5RMC3RMC1R | |
| SCHEMBL30800876 | 0.91 | C5AR1 (0.72) | C5AR1MC4RMC5RMC3RMC1R | |
| SCHEMBL29533782 | 0.90 | C5AR1 (0.77) | C5AR1MC4RMC5RMC3RMC1R | |
| SCHEMBL29430238 | 0.90 | MC4R (0.78) | C5AR1MC4RMC5RMC3RMC1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662782-B2 | Melanocortin 1 receptor selective compounds | ACTION PHARMA A/S (DK) | 2010-02-16 | — | — | US | disclosed |
| US-20070027086-A1 | Melanocortin 1 receptor selective compounds | SZARDENINGS MICHAEL | 2007-02-01 | — | — | US | disclosed |
| EP-1693382-A2 | Melanocortin 1 receptor selective compounds | Action Pharma A/S (DK) | 2006-08-23 | — | — | EP | disclosed |
| EP-1075492-B1 | MELANOCORTIN 1 RECEPTOR SELECTIVE COMPOUNDS | ACTION PHARMA AS (DK) | 2006-07-19 | — | — | EP | disclosed |
| EP-1075492-A1 | MELANOCORTIN 1 RECEPTOR SELECTIVE COMPOUNDS | Wa Pharm AB (SE) | 2001-02-14 | — | — | EP | disclosed |
| WO-1999057148-A1 | MELANOCORTIN 1 RECEPTOR SELECTIVE COMPOUNDS | WA PHARM AB (SE) | 1999-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027086-A1 | Melanocortin 1 receptor selective compounds | MC5R, MC1R, MC2R | C5AR1 183/4885MC4R 5/4885MC5R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.